A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : IRRs / infusion-related reactions

[Related PubMed/MEDLINE]
Total Number of Papers: 53
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   IRRs  (>> Co-occurring Abbreviation)
Long Form:   infusion-related reactions
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 A randomized phase I clinical trial comparing the pharmacokinetic, safety, and immunogenicity of potential biosimilar recombinant human HER2 monoclonal antibody for injection and trastuzumab in healthy Chinese adults. AUC, PK
2020 Daratumumab, lenalidomide, and dexamethasone in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma: a phase 1b study. D-Rd, DLT, NDMM
2020 Evaluation of Montelukast for the Prevention of Infusion-related Reactions With Daratumumab. ---
2020 Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis. ACR20, ADA, ADAb, ETN, INF, ISRs, RA
2020 Implementation and Evaluation of a 90-Minute Rituximab Infusion Protocol at the Richard L. Roudebush VA Medical Center. HCPs, RLRVAMC
2020 Increasing completion of asparaginase treatment in childhood acute lymphoblastic leukaemia (ALL): summary of an expert panel discussion. ALL, CNS, TDM
2020 Infusion-related reactions during Natalizumab treatment: Do we still need a post-infusion observation period? NTZ
2020 Ocrelizumab shorter infusion: Primary results from the ENSEMBLE PLUS substudy in patients with MS. OCR
2020 Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients. mAb, PD
10  2020 Prolonged methylprednisolone premedication prior to obinutuzumab in patients with chronic lymphocytic leukemia. AIHA, CLL
11  2020 Safety and Cost Benefits of the Rapid Daratumumab Infusion Protocol. ---
12  2020 Safety of ninety-minute daratumumab infusion. ---
13  2020 Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis. ---
14  2020 Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis. MS
15  2020 The Interaction of Innate and Adaptive Immunity and Stabilization of Mast Cell Activation in Management of Infusion Related Reactions in Patients with Fabry Disease. alpha-Gal A, ERT, FD
16  2019 A Prospective Trial Evaluating the Safety of a Shortened Infusion of Ramucirumab in Patients with Gastrointestinal Cancer. CI
17  2019 Incidence and Management of Olaratumab Infusion-Related Reactions. anti-alpha-Gal
18  2019 Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study. COO, DLBCL, SDI
19  2019 Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. MS, PPMS, RMS, s.c
20  2019 Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma. MPM
21  2019 The importance of early identification of infusion-related reactions to monoclonal antibodies. ---
22  2018 Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion. MM
23  2018 Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. ASCT, BV, CR, HL
24  2018 Efficacy and safety of the obinutuzumab-chlorambucil combination in the frontline treatment of elderly CLL patients with comorbidities - Polish Adult Leukemia Group (PALG) real-life analysis. CLL, CR, PALG, PFS, PR
25  2018 Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. AEs, ASCT, BV, HL, NIVO, R/R
26  2018 Safety of shortened infusion times for combined ipilimumab and nivolumab. ---
27  2018 Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials. AEs, irAEs, MedDRA, PD-L1, TRAEs
28  2018 Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153. ---
29  2017 A clinical prediction model for infusion-related reactions to rituximab in patients with B cell lymphomas. B-NHL, OR
30  2017 An update on the role of daratumumab in the treatment of multiple myeloma. DARA, mAbs, MM
31  2017 Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma. OS
32  2017 Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma. AEs, iNHL, OS, PFS
33  2017 Phenotyping and Visualizing Infusion-Related Reactions for Breast Cancer Patients. ---
34  2016 A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas. PK
35  2016 Managing Infusion-Related Reactions for Patients With Chronic Lymphocytic Leukemia Receiving Obinutuzumab. CLL
36  2016 Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. IgG1kappa, MM, RP2D
37  2015 Clinical development methodology for infusion-related reactions with monoclonal antibodies. mAbs
38  2015 Prevention and management of obinutuzumab-associated toxicities: Australian experience. CLL
39  2015 Role of obinutuzumab in the treatment of chronic lymphocytic leukemia. CLL
40  2015 Safety of Infusing Ipilimumab Over 30 Minutes. ---
41  2014 Incidence, risk factors, and management of infusion-related reactions in breast cancer patients receiving trastuzumab. ---
42  2014 Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma. DLBCL, FL
43  2014 Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study. RA
44  2014 The incidence and risk factors of infusion-related reactions to rituximab for treating B cell malignancies in a single tertiary hospital. ---
45  2013 Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. ---
46  2013 Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. DLBCL, MCL
47  2013 Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). AE, CR
48  2013 Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B. AmB
49  2012 Optimizing premedications in the prevention of bendamustine infusion-related reactions. CLL, FN
50  2011 Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter Outcome Survey (HOS). ERT, HOS, MPS II
51  2010 Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication. mCRC, OS, PFS
52  2008 Pre-medication practices and incidence of infusion-related reactions in patients receiving AMPHOTEC: data from the Patient Registry of Amphotericin B Cholesteryl Sulfate Complex for Injection Clinical Tolerability (PRoACT) registry. ABCD
53  2005 Tolerability and safety of rituximab (MabThera). RA